Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer and Biogen, Sitting in a Tree ... Well, Maybe

Matthew Herper writes in this article from Forbes that Pfizer, which is already "being name-dropped as a likely buyer" for the recently-on-the-market Biogen, would be making a mistake with such an acquisition. "Merging two pharmaceutical companies can do more harm than good, as a look at Pfizer's stock chart over the last decade shows," according to the article, suggesting that Pfizer's lack of productivity probably stems from a series of mergers that included acquisitions of Warner-Lambert and Pharmacia.


The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.